Navigation Links
VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Date:11/26/2007

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune stimulant approved for the treatment of hepatitis C, hepatitis B and a number of cancers. The open-label Phase IIa study is designed to enroll at least 12 more patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )

The Phase IIa trial will evaluate the clinical efficacy and biological effectiveness of Lenocta at the highest tolerable dose in combination with interferon alpha in patients with advanced-stage solid tumors.

"We have reached a significant milestone in the development of Lenocta as a potential cancer therapy with the initiation of this trial," said Michael D. Becker, President and Chief Executive Officer of VioQuest Pharmaceuticals. "We will continue to advance our portfolio of novel compounds for various cancer indications into clinical development, the goal of this drug development organization."

Razelle Kurzrock M.D., Professor of Medicine Chair, Department of Investigational Cancer Therapeutics at The University of Texas M.D. Anderson Cancer Center is the lead principal investigator for the study, while Aung Naing M.D. of the same institution and Claire Verschraegen M.D. of The University of New Mexico Cancer Center are participating co-principal investigators.

Data from the recently concluded Phase I trial for Lenocta demonstrated pharmacodynamic activity in some solid tumors as demonstrated by increases in the activities of natural killer cells, CD8 and type II dendritic cells.

About Lenocta

Lenocta, a pentavalent antimonial originally used for the treatment of the parasitic disease leishmaniasis, is an
'/>"/>

SOURCE VioQuest Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Tianyin Pharmaceutical Co., Inc. ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today updates the timeline for the ... The Company is scheduled to ... China Food & Drug Administration,s (CFDA) review in ...
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... , August 28, 2014 ... "DNA diagnostics Market (products, applications, techniques, end users ... Growth and Forecast, 2013 - 2020," indicates that ... billion by 2020 registering a CAGR of 9.8% ... accurate diagnosis and cost effectiveness over alternative diagnostic ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3
... 5, 2011 SyncMedical LLC today announced ... – Brazilian National Health Surveillance Agency) has approved their ... in Brazil. SyncMedical,s Ethos Spine product line was developed ... treatment solutions to surgeons in the ever-growing, ever-changing field ...
... Jan. 5, 2011 Heska Corporation (Nasdaq: HSKA ... Conference hosted by Sidoti & Company, LLC on Monday, January ... 42nd Street (Park Avenue at Grand Central) in New York ... Eastern Time. (Logo:   http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
Cached Medicine Technology:SyncMedical Receives ANVISA Regulatory Approval to Offer Spine and Internal Medicine Products in Brazil 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 Scientists from ... idea that progression-free survival correlates with overall survival of ... the new research. Click here to read it ... The Netherlands studied the cases of 523 mesothelioma ... studies. , “PFSR-18 [progression-free survival at 18 weeks ...
(Date:8/29/2014)... 2014 Edvance360, a leading provider of ... online teaching, as well as 2011 winner and six-time-finalist ... Management System, announced that their CTO, Brian Gerrity, and ... ALS Ice Bucket Challenge on behalf of Edvance360 Corporate ... Co-Founder. , “We know that the options were to ...
(Date:8/29/2014)... August 2014: A new ESC journal on cardiovascular pharmacotherapy ... and Oxford University Press. , European Heart Journal ... A special launch issue has been produced for ESC ... The journal,s website goes live in September. , Editor ... become the number one journal in the field of ...
(Date:8/29/2014)... When it comes to marketing, it’s important to create ... of MD Marketing Experts, is offering his expertise to ... and speaking events, while his company keeps on launching ... firm of medical marketing consultants, providing an all in ... strategies like web design, search engine optimization (SEO), pay-per-click ...
(Date:8/29/2014)... Today, Fecbek, a well-known female boots manufacturer and retailer, ... boots. The new items are offered in many styles, including ... All these products are nice-looking and elegant with the latest ... clients. , A boot is a type of footwear and ... foot and the ankle and extend up the leg, sometimes ...
Breaking Medicine News(10 mins):Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Edvance360 Participates In the ALS Ice Bucket Challenge (#ALSicebucketchallenge) 2Health News:ESC launches journal on CV pharmacotherapy 2Health News:MD Marketing Experts Evolution – Motivational Speaking, Workshops and New Websites Launch 2Health News:MD Marketing Experts Evolution – Motivational Speaking, Workshops and New Websites Launch 3Health News:Nice Boots for Sale at Fecbek.com 2
... Chemical compounds specially designed to neutralize proteins that would ... recognized for some time by scientists as a promising ... the November 16, 2007 issue of the journal Cell, ... how these antagonists of the anti-deathso-called Inhibitor-of-Apoptosis (IAP)proteins work ...
... year due to ... lung cancer --, -- More than 50% of new patients have ... according to the Lung Cancer Alliance --, ... early cancer detection, and The Thomas,G. Labrecque Foundation, a nonprofit organization that funds lung ...
... today announced that its Audit Committee has ... external auditors, that a,deemed dividend of $1,576,454 ... the Company,s financial statements by recording a ... in the consolidated,statement of operations for the ...
... sensing technologies have made exquisite measurements of brain ... measurements, computer scientists will now help neuroscientists discover ... result in the actions we take for granted, ... General Motors (GM) officials visited the Virginia Tech ...
... London, UK, 15 November, 2007 Reproductive Health Matters and ... Issue devoted to the celebration of the twentieth anniversary of ... in 1987. The November issue responds to the question ... yes − and no. , Globally, ...
... People who have experienced,the death of a ... dread.,Long-standing family traditions will never be the same; ... are replaced by depression and,loneliness. GriefShare, an ... a special "Surviving the Holidays" website to offer ...
Cached Medicine News:Health News:How 'IAP antagonist' chemicals kill tumors 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 2Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 3Health News:Canary Foundation and the Thomas G. Labrecque Foundation Launch a New Lung Cancer Early Detection Initiative 4Health News:Health Fitness Announces Non-Cash Adjustment and Restatement of 2006 Equity Investment Transaction Resulting in Delay for Filing Third Quarter Form 10-Q 2Health News:General Motors, Virginia Tech scientists collaborate to advance neuroinformatics 2Health News:General Motors, Virginia Tech scientists collaborate to advance neuroinformatics 3Health News:General Motors, Virginia Tech scientists collaborate to advance neuroinformatics 4Health News:November issue of Reproductive Health Matters focuses on maternal mortality 2Health News:Surviving the Holidays after a Loved One's Death 2
... designed to prevent lower body exposure to scattered ... any table where X-ray fluoroscopy is used. These ... applications where C-arm fluoroscopy units are used. Three ... each equipped with a 17 cm wide mounting ...
Pregnancy Apron...
All Day Comfort for the Lower Body...
Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....
Medicine Products: